Paolo Tarantino shared a post by Sarah Sammons, Medical Oncologist at Dana-Farber’s Breast Oncology Center on X:

“Grateful to have had the chance to e-join awesome colleagues Dr. Sarah Sammons and Dr. Aleix Prat and review novel frontiers in ADC development at Simposio International Cancer de Mama (SIOM) 2024, held in Santiago, Chile. Thanks to the organizers for the kind invitation— hope to be able to join in person next time!”

Quoting Sarah Sammons’ post on X:

“Fantastic time in the beautiful Santiago, Chile presenting at the Simposio International Cancer de Mama with Dr. Aleix Prat and Dr. Paolo Tarantino! 20 minutes on Post-CDK4/6 Landscape was a challenge.”

Source: Paolo Tarantino/X and Sarah Sammons/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.